Featured Research

from universities, journals, and other organizations

Probiotics do not help infants with colic, study finds

Date:
April 1, 2014
Source:
BMJ-British Medical Journal
Summary:
Giving probiotics to infants with colic does not appear to have any benefit, according to a large trial. Infant colic (excessive crying of unknown cause) affects up to 20% of infants and is a major burden to families and health services. Although it spontaneously resolves three to four months after birth, its cause remains elusive and no single effective treatment exists.

Probiotics cannot be routinely recommended for all infants with colic, say experts. These findings differ from previous smaller trials and do not support a general recommendation for the use of probiotics to treat colic in infants.

Infant colic (excessive crying of unknown cause) affects up to 20% of infants and is a major burden to families and health services. Although it spontaneously resolves three to four months after birth, its cause remains elusive and no single effective treatment exists.

Previous small trials suggest that the probiotic Lactobacillus reuteri effectively treats colic in breastfed infants. These studies, however, had limitations as they examined only a highly selective group of infants with colic. The effects of L reuteri on formula fed infants with colic are unknown.

So researchers based in Australia and Canada set out to determine whether the probiotic Lactobacillus reuteri reduces crying or fussing in 167 breastfed and formula fed infants with colic aged less than three months old.

A total of 85 infants were randomised to receive the probiotic and 82 to receive placebo for one month. Outcomes included daily duration of crying or fussing at one month, sleep duration, mother's mental health, family and infant quality of life.

Levels of gut microbial diversity, faecal calprotectin (a marker of gut inflammation) and E coli colonisation were also examined.

The results show that the probiotic group fussed significantly more than the placebo group at all time points from day seven to one month. At one month, the probiotic group cried or fussed 49 minutes more than the placebo group. This increased fussing occurred only in formula fed infants. L reuteri did not affect crying or fussing time in exclusively breastfed infants.

L reuteri treatment did not lead to changes in infant faecal microbial diversity, E coli colonisation, or calprotectin levels.

The researchers point out that this is the largest randomised controlled trial of probiotic intervention in infants with colic to date. They conclude that L reuteri treatment "did not reduce crying or fussing in infants with colic, nor was it effective in improving infant sleep, maternal mental health, family or infant functioning, or quality of life" and say "probiotics therefore cannot be routinely recommended for all infants with colic."

Further research is needed to identify which subgroups of infants with colic may benefit from probiotics, they add.

This represents the most definitive and well designed study to date on this controversial topic, writes William E Bennett Jr, Assistant Professor of Paediatrics at Indiana University School of Medicine, in an accompanying editorial.

With such a dearth of good evidence, should we be treating infant colic at all, he asks? He points out that children with colic "incur no serious long term effects" from the disorder and symptoms "abate with time," whereas the potential harm associated with diagnostic testing and treatment of infants "is likely to surpass the harm from colic itself."

As the old adage goes "babies cry," he concludes. Parents and their babies "may be better served if we devote more resources to studying the interventions recommended long before the discovery of probiotics: reassurance, family social support, and the tincture of time."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. V. Sung, H. Hiscock, M. L. K. Tang, F. K. Mensah, M. L. Nation, C. Satzke, R. G. Heine, A. Stock, R. G. Barr, M. Wake. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ, 2014; 348 (apr01 2): g2107 DOI: 10.1136/bmj.g2107

Cite This Page:

BMJ-British Medical Journal. "Probiotics do not help infants with colic, study finds." ScienceDaily. ScienceDaily, 1 April 2014. <www.sciencedaily.com/releases/2014/04/140401210408.htm>.
BMJ-British Medical Journal. (2014, April 1). Probiotics do not help infants with colic, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/04/140401210408.htm
BMJ-British Medical Journal. "Probiotics do not help infants with colic, study finds." ScienceDaily. www.sciencedaily.com/releases/2014/04/140401210408.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins